Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoprotein changes with statins.

Evan A Stein1, Donald M Black

  • 1Medical Research Laboratories International, 2 Tesseneer Avenue, Highland Heights, KY 41076, USA. ESteinMRL@aol.com

Current Atherosclerosis Reports
|January 5, 2002
PubMed
Summary

This study assesses how statins and lipid drugs impact lipid fractions. It reviews recent research focusing on their effects on triglycerides, high-density lipoprotein cholesterol, and cardiovascular risk markers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Journal of lipid research·2026
Same author

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

JAMA cardiology·2026
Same author

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.

The lancet. Diabetes & endocrinology·2025
Same author

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

JAMA cardiology·2024
Same author

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.

European heart journal·2022
Same author

Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.

Journal of clinical lipidology·2022

Area of Science:

  • Pharmacology and Cardiovascular Medicine

Background:

  • Statins and lipid-lowering drugs are crucial for managing cardiovascular risk.
  • Recent research often compares statin effects on triglycerides and high-density lipoprotein cholesterol.
  • Non-lipid effects and novel cardiovascular risk markers like high-sensitivity C-reactive protein are also areas of recent focus.

Purpose of the Study:

  • To assess the impact of statins and other lipid drugs on specific lipid fractions.
  • To review current literature on the comparative effects of statins.
  • To examine the focus of recent research regarding lipid drugs and cardiovascular risk.

Main Methods:

  • Literature review of recent scientific papers.
  • Analysis of studies comparing lipid drug effects on lipid fractions.
  • Examination of research on non-lipid effects and emerging cardiovascular risk markers.

Main Results:

  • Existing literature extensively covers statins' effects on lipid profiles.
  • Recent studies increasingly compare statin efficacy on triglycerides and HDL cholesterol.
  • Emerging research explores non-lipid pleiotropic effects and markers like hs-CRP.

Conclusions:

  • Understanding the multifaceted effects of lipid-modifying drugs is essential.
  • Comparative analysis of statins on key lipid parameters remains a significant research area.
  • Incorporating novel risk factors like hs-CRP provides a more comprehensive view of cardiovascular risk management.

Related Experiment Videos